Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
An FDA adcom votes in favour of expansion into a multiple myeloma precursor.
Starglo isn't applicable to a US population, an adcom rules.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
PF-08046037 joins PF-08046054 in clinical development.
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
